RxDoctor Payments Data

Ramesh Gadiraju, MD

Hospitalist · Des Moines, IANPI 1699087007

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Medtronic at 51.3% of the total. 2024 is the largest year on record at $240, 2.2 times the $109 reported in 2019. Among hospitalist clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$468in general payments, 2019–2025

Across 13 payments — averaging $36.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$240
  • UCB, Inc.$74
  • Pfizer$45
  • Johnson & Johnson$36
  • Boston Scientific$23
  • Boehringer Ingelheim$19
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$468100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$468 in reported general payments places this provider in the 90th percentile of 223 hospitalist providers in Iowa.

See all hospitalist providers in Iowa

Medicare billing

Part B allowed, 2024
$125,866
Medicare patients
262
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$22,812
Midodrine Hcl15$433
Amlodipine Besylate51$255
Atorvastatin Calcium40$226
Metoprolol Tartrate30$212
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$189
Losartan Potassium13$182
Levothyroxine Sodium26$174
Pantoprazole Sodium29$159
Torsemide13$158
Hydralazine Hcl18$146
Metoprolol Succinate26$140
ClopidogrelClopidogrel Bisulfate16$130
Digoxin11$126
Bisoprolol Fumarate11$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$22,81242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 hospitalist providers in Iowa.

Other hospitalist in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →